Appendix A In Table A1, we list the concomitant medications of ziprasidone- and placebo-treated groups. Table A1. Concomitant medications of ziprasidone- and placebo-treated groups. Medication Placebo (N = 6) Ziprasidone (N = 8) Total (N = 14) n n n Antidepressants Amitriptyline 1 0 1 Bupropion 3 0 3 Citalopram 0 2 2 Desvenlafaxine 0 1 1 Escitalopram 2 0 2 Trazodone 1 1 2 Venlafaxine 1 1 2 Total 8 5 13 Mood stabilizers Lamotrigine
2 0 2 Lithium 1 3 4 Valproic acid 2 2 4 Total Inhibitors,research,lifescience,medical 5 6 10 Benzodiazepines Clonazepam 2 1 3 Lorazepam 0 1 1 Total 2 2 4 Other Clonidine 0 1 1 Concerta 1 0 1 Gabapentin 1 0 1 Imovane 1 0 1 Methadone 0 1 1 OxyContin 1 0 1 Total 4 2 6 View it in a separate window Footnotes Funding: This work was supported by an investigator-initiated research grant from Pfizer Canada as awarded to R. Milev. Conflict of interest statement: R. Milev is on Speaker/Src inhibitor Advisory Boards for, or has received research funds from: AstraZeneca, Biovail, BrainCells Inhibitors,research,lifescience,medical Inc., Canadian Network for Mood & Anxiety Treatments, Eli Lilly, Janssen-Ortho, Lundbeck, Pfizer, Servier, Takeda, Wyeth, Bristol-Myers Squibb and Merck. Contributor Information Anusha Baskaran, Centre for Neuroscience Studies, Queen’s University, Providence Care, Mental Health Services, Kingston, Ontario, Canada. Dave Summers, Centre for Neuroscience Studies, Queen’s University,
Providence Care, Mental Health Services, Kingston, Inhibitors,research,lifescience,medical Ontario, Canada. Stephanie LM Willing, Queen’s University, Providence Care, Mental Health Services, Kingston, Ontario, Canada. Ruzica Jokic, Department of Psychiatry, Queen’s University, Providence Care, Mental Health Services, Kingston, Ontario, Canada. Roumen Milev, Department of Psychiatry, Queen’s University, Inhibitors,research,lifescience,medical 752
King Street West, Kingston, Ontario, Canada K7L 4X3.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor (bradykinesia, rigidity and resting tremors) and nonmotor symptoms (cognitive impairment, affective and behavioral disturbances, impairment of the autonomic nervous system) [Chaudhury et al. 2006]. Cognitive impairments may be present Inhibitors,research,lifescience,medical at an early stage in newly diagnosed drug-naïve patients [Poletti et al. 2012b], with deficits being most prominent in the domains of executive functions, Bay 11-7085 episodic memory and visuospatial functions [Muslimovic et al. 2005]. Prospective studies showed that up to 75–80% of PD patients may eventually develop dementia during the course of the disease, with akinetic-dominant phenotype, early presence of hallucinations and cognitive impairment being the risk factors [Aarsland et al. 2003; Santangelo et al. 2007]. Considering the severe impact of cognitive impairment on the quality of life of PD patients and their families [Schrag et al. 2000], the investigation of factors that may prevent, improve or worsen cognitive impairment represents an important topic in the management of these patients.